Christiane Rudolph
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Christiane Rudolph has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Katalinic
Institute of Social Medicine and Epidemiology, University of Luebeck, Luebeck, Germany
5 shared publications Alexander Katalinic
3 shared publications- Heinz Handels
University of Luebeck
3 shared publications - Natalie Rath
Saarland Cancer Registry, Neugeländstraße 9, 66117 Saarbrücken, Germany
3 shared publications - Sebastian Germer
German Research Center for Artificial Intelligence (DFKI), Ratzeburger Allee 160, 23562 Lübeck, Germany
3 shared publications Katharina Rausch
Saarland Cancer Registry, Neugeländstraße 9, 66117 Saarbrücken, Germany
2 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Elsevier in SSRN Electronic Journal
Epidemiology of metastatic breast cancer among women between 1993 and 2022 in the federal state of Saarland, Germany
With more than 2.3 million new cases diagnosed each year worldwide, invasive breast cancer (BC) is the most common malignant neoplasm among women. A proportion of patients is diagnosed with initial distant metastases (de novo metastatic breast cancer, dnMBC), while others develop distant metastases following initial diagnosis (recurrent metastatic breast cancer, rMBC).The aim of this study is to show trends in dnMBC and rMBC rates in the federal state of Saarland, Germany, over a time period of 30 years from 1993 to 2022. Age-specific and age-standardized rates were calculated, based on data from the Saarland Cancer Registry (CR). Annual Percent Changes (APC) were estimated in Joinpoint regression models to describe trends.While dnMBC showed a steady and significant increase in the age-standardized rate (APC = 1.6, 95 %-CI: [0.87; 2.46]), a steep increase was noticeable in dnMBC in the age-specific rate in women over 70 years after 2007 (2007–2022: APC = 3.94, 95 %-CI: [1.66; 15.25]). Overall, the age-standardized rate in rMBC declined slightly, as did the age-specific rates in younger and middle-aged women. In contrast, the age-specific rate of rMBC in women over 70 years inclined clearly.This analysis showed long term trends of dnMBC and rMBC in a German population. The increase of dnMBC and decline of rMBC can be explained by the overall increase of BC, sensitivity of diagnostic procedures, more intensive staging and improved completeness of registration. This study showed the usefulness of CRs to provide clinically relevant outcome measures and trends over time.
- 28 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEpidemiology of metastatic breast cancer among women between 1993 and 2022 in the federal state of Saarland, Germany
With more than 2.3 million new cases diagnosed each year worldwide, invasive breast cancer (BC) is the most common malignant neoplasm among women. A proportion of patients is diagnosed with initial distant metastases (de novo metastatic breast cancer, dnMBC), while others develop distant metastases following initial diagnosis (recurrent metastatic breast cancer, rMBC).The aim of this study is to show trends in dnMBC and rMBC rates in the federal state of Saarland, Germany, over a time period of 30 years from 1993 to 2022. Age-specific and age-standardized rates were calculated, based on data from the Saarland Cancer Registry (CR). Annual Percent Changes (APC) were estimated in Joinpoint regression models to describe trends.While dnMBC showed a steady and significant increase in the age-standardized rate (APC = 1.6, 95 %-CI: [0.87; 2.46]), a steep increase was noticeable in dnMBC in the age-specific rate in women over 70 years after 2007 (2007–2022: APC = 3.94, 95 %-CI: [1.66; 15.25]). Overall, the age-standardized rate in rMBC declined slightly, as did the age-specific rates in younger and middle-aged women. In contrast, the age-specific rate of rMBC in women over 70 years inclined clearly.This analysis showed long term trends of dnMBC and rMBC in a German population. The increase of dnMBC and decline of rMBC can be explained by the overall increase of BC, sensitivity of diagnostic procedures, more intensive staging and improved completeness of registration. This study showed the usefulness of CRs to provide clinically relevant outcome measures and trends over time.
- 4 July 2026
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 220, 106586
Harmonizing regional cancer registry data to facilitate Germany-wide epidemiological analyses
- 4 July 2026
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 220, 106586
Harmonizing regional cancer registry data to facilitate Germany-wide epidemiological analyses
- Open Access
- 26 August 2024
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 191, 105607
Survival analysis for lung cancer patients: A comparison of Cox regression and machine learning models
- 26 August 2024
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 191, 105607
Open AccessSurvival analysis for lung cancer patients: A comparison of Cox regression and machine learning models
- Open Access
Colorectal Cancer Survival in German–Danish Border Regions—A Registry-Based Cohort Study
The aim of this study was (i) to update the reporting of colorectal cancer survival differences over time in the German–Danish border region (Schleswig-Holstein, Southern Denmark, and Zealand) and (ii) to assess the extent to which it can be explained by stage and primary treatment. Incident invasive colorectal cancer cases diagnosed from 2004 to 2016 with a follow-up of vital status through 31 December 2017 were extracted from cancer registries. Analyses were conducted by anatomical subsite and for four consecutive periods. Kaplan–Meier curves and log-rank tests were computed. Cox regression models using data from Schleswig-Holstein from 2004 to 2007 as the reference category were run while controlling for age, sex, stage, and treatment. The cox regression models showed decreasing hazard ratios of death for all three regions over time for both anatomical subsites. The improvement was stronger in the Danish regions, and adjustment for age, sex, stage, and treatment attenuated the results only slightly. In 2014–2016, colon cancer survival was similar across regions, while rectal cancer survival was significantly superior in the Danish regions. Regional survival differences can only partially be explained by differing stage distribution and treatment and may be linked additionally to healthcare system reforms and screening efforts.
Open AccessColorectal Cancer Survival in German–Danish Border Regions—A Registry-Based Cohort Study
The aim of this study was (i) to update the reporting of colorectal cancer survival differences over time in the German–Danish border region (Schleswig-Holstein, Southern Denmark, and Zealand) and (ii) to assess the extent to which it can be explained by stage and primary treatment. Incident invasive colorectal cancer cases diagnosed from 2004 to 2016 with a follow-up of vital status through 31 December 2017 were extracted from cancer registries. Analyses were conducted by anatomical subsite and for four consecutive periods. Kaplan–Meier curves and log-rank tests were computed. Cox regression models using data from Schleswig-Holstein from 2004 to 2007 as the reference category were run while controlling for age, sex, stage, and treatment. The cox regression models showed decreasing hazard ratios of death for all three regions over time for both anatomical subsites. The improvement was stronger in the Danish regions, and adjustment for age, sex, stage, and treatment attenuated the results only slightly. In 2014–2016, colon cancer survival was similar across regions, while rectal cancer survival was significantly superior in the Danish regions. Regional survival differences can only partially be explained by differing stage distribution and treatment and may be linked additionally to healthcare system reforms and screening efforts.
- 1 October 2021
- Published by Elsevier in Cancer Epidemiology
- Vol. 74, 102001
Survival of breast cancer patients in German-Danish border regions – A registry-based cohort study
- 1 October 2021
- Published by Elsevier in Cancer Epidemiology
- Vol. 74, 102001
Survival of breast cancer patients in German-Danish border regions – A registry-based cohort study
- Open Access
- 1 November 2019
- Published by Springer Nature in BMC Health Services Research
- Vol. 19 (1) , 1-13
The acceptance and applicability of a patient-reported experience measurement tool in oncological care: a descriptive feasibility study in northern Germany
Background: Patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) are tools for assessing outcomes of and experiences with health care from the patient’s perspective. In Germany, PROMs are widely used in research for evaluating patient outcomes and quality of care. However, the application of PREMs is rather scant, especially in oncology. The study aimed to assess the feasibility of patient-centred quality evaluation in oncological care in Germany using the German adaptation of the Danish National Cancer Patient Questionnaire. This questionnaire is a PREM/PROM-tool addressing patients of all cancer sites and covering the entire cancer patient pathway. Methods: The Danish National Cancer Patient Questionnaire was translated into German via forward-backward translation. Face-validity was tested among three cancer patients in a conventional pre-test. The German adaptation contains 99 questions. A pilot test was carried out among 245 newly diagnosed breast and colorectal cancer patients in the German federal state Schleswig-Holstein. Patients were recruited via clinics participating in the Oncological Care Registry (12 specialised units in seven hospitals) and contacted six to nine months after diagnosis. Response behaviour and response patterns were compared to the Danish study population (n = 1964). Results: The willingness among clinicians to support patient recruitment as well as the response rate of patients to the questionnaire was high (65%). Moreover, response behaviour and response patterns of German and Danish patients were consistent. Despite the generally good response behaviour of patients to the single items, the authors observed that questions assessing the diagnostic process did not fully capture German pathways. Only 19.3% of the German patients stated that their diagnostic process was initiated by a visit to a general practitioner (GP) in contrast to 52% in Denmark. The assessment of patient experiences in the diagnostic phase heavily focuses on experiences in general practice, which does not seem appropriate in the German health care setting. Conclusion: The translation was successful, and the feasibility of a future large-scale study within existing structures is given. However, some modifications of questions heavily related to the Danish health care system, especially referring to the diagnostic phase, are necessary.
- 1 November 2019
- Published by Springer Nature in BMC Health Services Research
- Vol. 19 (1) , 1-13
Open AccessThe acceptance and applicability of a patient-reported experience measurement tool in oncological care: a descriptive feasibility study in northern Germany
Background: Patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) are tools for assessing outcomes of and experiences with health care from the patient’s perspective. In Germany, PROMs are widely used in research for evaluating patient outcomes and quality of care. However, the application of PREMs is rather scant, especially in oncology. The study aimed to assess the feasibility of patient-centred quality evaluation in oncological care in Germany using the German adaptation of the Danish National Cancer Patient Questionnaire. This questionnaire is a PREM/PROM-tool addressing patients of all cancer sites and covering the entire cancer patient pathway. Methods: The Danish National Cancer Patient Questionnaire was translated into German via forward-backward translation. Face-validity was tested among three cancer patients in a conventional pre-test. The German adaptation contains 99 questions. A pilot test was carried out among 245 newly diagnosed breast and colorectal cancer patients in the German federal state Schleswig-Holstein. Patients were recruited via clinics participating in the Oncological Care Registry (12 specialised units in seven hospitals) and contacted six to nine months after diagnosis. Response behaviour and response patterns were compared to the Danish study population (n = 1964). Results: The willingness among clinicians to support patient recruitment as well as the response rate of patients to the questionnaire was high (65%). Moreover, response behaviour and response patterns of German and Danish patients were consistent. Despite the generally good response behaviour of patients to the single items, the authors observed that questions assessing the diagnostic process did not fully capture German pathways. Only 19.3% of the German patients stated that their diagnostic process was initiated by a visit to a general practitioner (GP) in contrast to 52% in Denmark. The assessment of patient experiences in the diagnostic phase heavily focuses on experiences in general practice, which does not seem appropriate in the German health care setting. Conclusion: The translation was successful, and the feasibility of a future large-scale study within existing structures is given. However, some modifications of questions heavily related to the Danish health care system, especially referring to the diagnostic phase, are necessary.
- 22 June 2018
- Published by Georg Thieme Verlag KG in Das Gesundheitswesen
- Vol. 81 (12) , 993-1000
Basisinzidenz HPV-assoziierter invasiver und in situ Karzinome in Deutschland vor Eintreten möglicher Impfeffekte
Ziel der Studie In Deutschland steht seit März 2007 die Impfung gegen humane Papillomaviren (HPV) als Leistung der GKV zur Verfügung. Neben der Reduktion der Krankheitslast durch Zervixkarzinome, wird ein positiver Effekt auf andere HPV-assoziierte Karzinome erwartet. Für Deutschland liegen derzeit keine veröffentlichten Angaben zu Basisinzidenzen HPV-assoziierter Karzinome vor Einführung des Impfstoffs vor, obwohl diese für die Beurteilung der Effekte der HPV-Impfung erforderlich sind. Ziel der vorliegenden Arbeit ist es, diese Wissenslücke zu schließen. Methodik Auf Basis von Krebsregisterdaten aus 7 deutschen Bundesländern wurden durchschnittliche, jährliche Inzidenzraten für Zervix-, Anogenital-, Mundhöhlen- und Oropharynxkrebs im Zeitraum von 2003 bis 2007 berechnet. Ergänzend werden Trendverläufe bis 2013 dargestellt. Für ganz Deutschland geben zusätzliche Fallzahlschätzungen einen Überblick über die absolute Krankheitslast durch HPV-assoziierte Karzinome. Ergebnisse Deutschlandweit erkrankten vor Einführung der HPV-Schutzimpfung jährlich schätzungsweise 11 686 Personen neu an einer invasiven HPV-assoziierten Krebserkrankung. Am häufigsten sind Zervixkarzinome bei Frauen (4 387 Fälle) und Mundhöhlen- und Oropharynxkarzinome bei Männern (2 770 Fälle) mit altersstandardisierten Inzidenzraten von jeweils 8,8 und 5,9 Fällen pro 100 000 Personen. Die alterstandardisierte Inzidenzrate von in situ Zervixkarzinomen beträgt 23,5 Fälle pro 100 000 Frauen. Die Inzidenzverläufe zeigen signifikante Anstiege bei Vulva-, Penis- und Anorektalkarzinomen. Schlussfolgerung Die vorliegende Arbeit biete robuste Basisdaten zur Inzidenz HPV-assoziierter Karzinome vor Einführung der HPV-Schutzimpfung in Deutschland. Erste Effekte der Impfung auf die Erkrankungshäufigkeit von HPV-assoziierten Karzinomen in Deutschland können sinnvoll frühestens ab 2019 untersucht werden. Aim Vaccines against human papillomaviruses are covered by statutory health insurances in Germany since March 2007. A reduction of cervical and other HPV-associated cancers is expected. Incidence rates of HPV-associated cancers preceding the introduction of vaccines are unknown. These, however, are important for assessing the effects of HPV vaccines. The aim of the present study was to bridge this knowledge gap. Methods Based on cancer registry data from seven federal states, average yearly incidence rates for cervical, anogenital, oropharyngeal cancers and cancers of the oral cavity were calculated for the period 2003 to 2007. Additionally, estimated numbers of cases give an overview on the total burden of disease caused by HPV-associated cancers in Germany. Incidence trends from 2003 to 2013 are also presented. Results In Germany, 11,686 cases of invasive HPV-associated cancers occurred yearly before the introduction of HPV vaccines. The most common sites are cervical cancers for women (4,387 cases) and oropharyngeal cancers for men (2,770 cases) with age-standardized incidence rates of 8.8 and 5.9 cases per 100,000 persons, respectively. The age-standardized incidence rate for in situ cervical cancers amounts to 23.5 cases per 100 000 women. Incidence trends show significant increases of invasive vulvar, penile and anorectal cancers. Conclusion This work presents robust incidence data of HPV-associated cancers in Germany prior to the introduction of the HPV vaccine. Effects of HPV vaccines on the incidence of HPV-associated cancers can be estimated for Germany earliest in 2019.
- 22 June 2018
- Published by Georg Thieme Verlag KG in Das Gesundheitswesen
- Vol. 81 (12) , 993-1000
Basisinzidenz HPV-assoziierter invasiver und in situ Karzinome in Deutschland vor Eintreten möglicher Impfeffekte
Ziel der Studie In Deutschland steht seit März 2007 die Impfung gegen humane Papillomaviren (HPV) als Leistung der GKV zur Verfügung. Neben der Reduktion der Krankheitslast durch Zervixkarzinome, wird ein positiver Effekt auf andere HPV-assoziierte Karzinome erwartet. Für Deutschland liegen derzeit keine veröffentlichten Angaben zu Basisinzidenzen HPV-assoziierter Karzinome vor Einführung des Impfstoffs vor, obwohl diese für die Beurteilung der Effekte der HPV-Impfung erforderlich sind. Ziel der vorliegenden Arbeit ist es, diese Wissenslücke zu schließen. Methodik Auf Basis von Krebsregisterdaten aus 7 deutschen Bundesländern wurden durchschnittliche, jährliche Inzidenzraten für Zervix-, Anogenital-, Mundhöhlen- und Oropharynxkrebs im Zeitraum von 2003 bis 2007 berechnet. Ergänzend werden Trendverläufe bis 2013 dargestellt. Für ganz Deutschland geben zusätzliche Fallzahlschätzungen einen Überblick über die absolute Krankheitslast durch HPV-assoziierte Karzinome. Ergebnisse Deutschlandweit erkrankten vor Einführung der HPV-Schutzimpfung jährlich schätzungsweise 11 686 Personen neu an einer invasiven HPV-assoziierten Krebserkrankung. Am häufigsten sind Zervixkarzinome bei Frauen (4 387 Fälle) und Mundhöhlen- und Oropharynxkarzinome bei Männern (2 770 Fälle) mit altersstandardisierten Inzidenzraten von jeweils 8,8 und 5,9 Fällen pro 100 000 Personen. Die alterstandardisierte Inzidenzrate von in situ Zervixkarzinomen beträgt 23,5 Fälle pro 100 000 Frauen. Die Inzidenzverläufe zeigen signifikante Anstiege bei Vulva-, Penis- und Anorektalkarzinomen. Schlussfolgerung Die vorliegende Arbeit biete robuste Basisdaten zur Inzidenz HPV-assoziierter Karzinome vor Einführung der HPV-Schutzimpfung in Deutschland. Erste Effekte der Impfung auf die Erkrankungshäufigkeit von HPV-assoziierten Karzinomen in Deutschland können sinnvoll frühestens ab 2019 untersucht werden. Aim Vaccines against human papillomaviruses are covered by statutory health insurances in Germany since March 2007. A reduction of cervical and other HPV-associated cancers is expected. Incidence rates of HPV-associated cancers preceding the introduction of vaccines are unknown. These, however, are important for assessing the effects of HPV vaccines. The aim of the present study was to bridge this knowledge gap. Methods Based on cancer registry data from seven federal states, average yearly incidence rates for cervical, anogenital, oropharyngeal cancers and cancers of the oral cavity were calculated for the period 2003 to 2007. Additionally, estimated numbers of cases give an overview on the total burden of disease caused by HPV-associated cancers in Germany. Incidence trends from 2003 to 2013 are also presented. Results In Germany, 11,686 cases of invasive HPV-associated cancers occurred yearly before the introduction of HPV vaccines. The most common sites are cervical cancers for women (4,387 cases) and oropharyngeal cancers for men (2,770 cases) with age-standardized incidence rates of 8.8 and 5.9 cases per 100,000 persons, respectively. The age-standardized incidence rate for in situ cervical cancers amounts to 23.5 cases per 100 000 women. Incidence trends show significant increases of invasive vulvar, penile and anorectal cancers. Conclusion This work presents robust incidence data of HPV-associated cancers in Germany prior to the introduction of the HPV vaccine. Effects of HPV vaccines on the incidence of HPV-associated cancers can be estimated for Germany earliest in 2019.
- 30 October 2017
- Published by Springer Nature in Journal of Autism and Developmental Disorders
- Vol. 48 (2) , 619-624
Brief Report: Sexual Orientation in Individuals with Autistic Traits: Population Based Study of 47,000 Adults in Stockholm County
We examined the association between autistic traits and sexual orientation in a general adult population (N = 47,356). Autistic traits were measured with the ten items Autistic Quotient questionnaire using a cut-off score of ≥ 6. Sexual orientation was assessed by self-report. Multinomial logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for sexual orientation categories. Participants with autistic traits were more likely to identify as bisexual (OR 1.73; 95% CI 1.01–2.9) and to feel that their sexual orientation could neither be described as hetero-, homo- nor bisexual (OR 3.05; 95% CI 2.56–3.63), compared to individuals without autistic traits. Autistic traits are associated with minority sexual orientation, and perhaps with uncertain self-identification and/or a defiance of traditional ways of categorizing sexual identity.
- 30 October 2017
- Published by Springer Nature in Journal of Autism and Developmental Disorders
- Vol. 48 (2) , 619-624
Brief Report: Sexual Orientation in Individuals with Autistic Traits: Population Based Study of 47,000 Adults in Stockholm County
We examined the association between autistic traits and sexual orientation in a general adult population (N = 47,356). Autistic traits were measured with the ten items Autistic Quotient questionnaire using a cut-off score of ≥ 6. Sexual orientation was assessed by self-report. Multinomial logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for sexual orientation categories. Participants with autistic traits were more likely to identify as bisexual (OR 1.73; 95% CI 1.01–2.9) and to feel that their sexual orientation could neither be described as hetero-, homo- nor bisexual (OR 3.05; 95% CI 2.56–3.63), compared to individuals without autistic traits. Autistic traits are associated with minority sexual orientation, and perhaps with uncertain self-identification and/or a defiance of traditional ways of categorizing sexual identity.
- 27 July 2015
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 13 (8) , 788-797
Incidence trends of nonmelanoma skin cancer in Germany from 1998 to 2010
Summary: Background and objectives: Nonmelanoma skin cancer (NMSC) is the most common malignant neoplasm in Germany. However, little is known about incidence trends of NMSC and its main subtypes basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in Germany.Material and methods: Cancer registry data from fourteen German federal states was used to estimate age‐standardized incidence rates by histologic subtype. Annual percentage changes (APC) were estimated in joinpoint regression models, in order to assess trend shifts in the years from 1998 to 2010.Results: In Germany, incidence rates of NMSC showed a significant increase from 43.1 cases/100 000 in 1998 to 105.2 cases/100 000 in 2010. Incidence rates and incidence increases revealed large regional variations. Basal cell carcinoma was the most common tumor followed by SCC. Men were more frequently affected than women, but incidence increases were steeper in women.Conclusions: Results are consistent with national and international observations. The heterogeneity of incidence rates and their changes among federal states indicate that incidence changes are most likely related to improved case registration practices in German cancer registries.
- 27 July 2015
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 13 (8) , 788-797
Incidence trends of nonmelanoma skin cancer in Germany from 1998 to 2010
Summary: Background and objectives: Nonmelanoma skin cancer (NMSC) is the most common malignant neoplasm in Germany. However, little is known about incidence trends of NMSC and its main subtypes basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in Germany.Material and methods: Cancer registry data from fourteen German federal states was used to estimate age‐standardized incidence rates by histologic subtype. Annual percentage changes (APC) were estimated in joinpoint regression models, in order to assess trend shifts in the years from 1998 to 2010.Results: In Germany, incidence rates of NMSC showed a significant increase from 43.1 cases/100 000 in 1998 to 105.2 cases/100 000 in 2010. Incidence rates and incidence increases revealed large regional variations. Basal cell carcinoma was the most common tumor followed by SCC. Men were more frequently affected than women, but incidence increases were steeper in women.Conclusions: Results are consistent with national and international observations. The heterogeneity of incidence rates and their changes among federal states indicate that incidence changes are most likely related to improved case registration practices in German cancer registries.